222 related articles for article (PubMed ID: 27926505)
1. Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.
Lugini L; Sciamanna I; Federici C; Iessi E; Spugnini EP; Fais S
Oncotarget; 2017 Jan; 8(3):4147-4155. PubMed ID: 27926505
[TBL] [Abstract][Full Text] [Related]
2. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
Azzarito T; Venturi G; Cesolini A; Fais S
Cancer Lett; 2015 Jan; 356(2 Pt B):697-703. PubMed ID: 25449440
[TBL] [Abstract][Full Text] [Related]
3. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Federici C; Lugini L; Marino ML; Carta F; Iessi E; Azzarito T; Supuran CT; Fais S
J Enzyme Inhib Med Chem; 2016; 31(sup1):119-125. PubMed ID: 27142956
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
DeStefano JJ
Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
6. Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilization‑associated cell death.
Takeda A; Takano N; Kokuba H; Hino H; Moriya S; Abe A; Hiramoto M; Tsukahara K; Miyazawa K
Int J Oncol; 2020 Dec; 57(6):1280-1292. PubMed ID: 33173988
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
Canitano A; Iessi E; Spugnini EP; Federici C; Fais S
Cancer Lett; 2016 Jul; 376(2):278-83. PubMed ID: 27084522
[TBL] [Abstract][Full Text] [Related]
8. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
[TBL] [Abstract][Full Text] [Related]
9. Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells.
Bellisai C; Sciamanna I; Rovella P; Giovannini D; Baranzini M; Pugliese GM; Zeya Ansari MS; Milite C; Sinibaldi-Vallebona P; Cirilli R; Sbardella G; Pichierri P; Trisciuoglio D; Lavia P; Serafino A; Spadafora C
Cancer Lett; 2020 May; 478():133-145. PubMed ID: 32112906
[TBL] [Abstract][Full Text] [Related]
10. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
Haubrich RH; Riddler SA; Ribaudo H; Direnzo G; Klingman KL; Garren KW; Butcher DL; Rooney JF; Havlir DV; Mellors JW;
AIDS; 2011 Nov; 25(18):2269-78. PubMed ID: 21941167
[TBL] [Abstract][Full Text] [Related]
11. Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells.
Jamaluddin MS; Lin PH; Yao Q; Chen C
Atherosclerosis; 2010 Jan; 208(1):104-11. PubMed ID: 19674747
[TBL] [Abstract][Full Text] [Related]
12. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
13. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
Yu M; Lee C; Wang M; Tannock IF
Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
Braz VA; Holladay LA; Barkley MD
Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
[TBL] [Abstract][Full Text] [Related]
15. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
Bélanger AS; Caron P; Harvey M; Zimmerman PA; Mehlotra RK; Guillemette C
Drug Metab Dispos; 2009 Sep; 37(9):1793-6. PubMed ID: 19487252
[TBL] [Abstract][Full Text] [Related]
16. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
Wang J; Liang H; Bacheler L; Wu H; Deriziotis K; Demeter LM; Dykes C
Virology; 2010 Jul; 402(2):228-37. PubMed ID: 20399480
[TBL] [Abstract][Full Text] [Related]
17. HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
Mitchell D; Israr M; Alam S; Dinello D; Kishel J; Jia R; Meyers C
HIV Med; 2014 Apr; 15(4):196-202. PubMed ID: 24580719
[TBL] [Abstract][Full Text] [Related]
18. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD
Retrovirology; 2009 May; 6():44. PubMed ID: 19439089
[TBL] [Abstract][Full Text] [Related]
19. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Hukezalie KR; Thumati NR; Côté HC; Wong JM
PLoS One; 2012; 7(11):e47505. PubMed ID: 23166583
[TBL] [Abstract][Full Text] [Related]
20. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.
De Milito A; Canese R; Marino ML; Borghi M; Iero M; Villa A; Venturi G; Lozupone F; Iessi E; Logozzi M; Della Mina P; Santinami M; Rodolfo M; Podo F; Rivoltini L; Fais S
Int J Cancer; 2010 Jul; 127(1):207-19. PubMed ID: 19876915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
